Navigation Links
Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)
Date:4/15/2008

FRESNO, Calif., April 15 /PRNewswire/ -- Chairman & CEO, Paul Willis stated, "Just like his previous career at a large agribusiness company, Dr. Mark E. Whitacre has risen fast at Cypress Systems, Inc, last month being named the company's chief operating officer and president of operations." Now Cypress and Whitacre are focusing their energy on an aggressive cancer prevention campaign in order to get Americans -- and people around the world -- to consume a special type of selenium known as SelenoExcell(R). SelenoExcell(R) was found in a gold-standard human clinical trial to dramatically reduce colon, prostate, and lung cancers.

*(PHOTO 72dpi: Send2Press.com/mediaboom/08-0415-Whitacre_72dpi.jpg)

*(Photo Caption: Dr. Mark E. Whitacre.)

Mark Whitacre is the subject of a motion picture to be filmed starting next month, titled, "The Informant," with box office mega star Matt Damon playing Whitacre. However, Whitacre's real mission in life and main passion for the future is focused on the role of selenium and SelenoExcell(R) as a cancer prevention agent. Cypress believes that with the anticipated media coverage related to the movie, there will be a window of opportunity to raise public awareness for SelenoExcell(R) and cancer prevention.

Awarded his Ph.D. at Cornell University, Dr. Whitacre did his research thesis on the biochemical role of selenium at the cellular level. His research was conducted jointly with a world-renowned selenium scientist, Dr. G.F. Combs, Jr. Dr. Whitacre today stated, "Although sadly underutilized, selenium has the potential to have the most profound impact upon dietary cancer prevention of any nutrient we know of today."

Cancer rates per 100,000 people are about the same as they were 40 years ago! According to the American Cancer Society, 565,650 people are expected to die this year due to cancer in the USA, and 1,437,180 people are expected to have cancer in 2008. "These cancer incidence and death rate due to cancer are unacceptable," said Dr. Whitacre. He further added, "Selenium acts as an active component of the important enzyme, glutathione peroxidase, which helps combat free radicals. Free radicals are part of the cause of many chronic diseases including cancer. Selenium plays a vital role in our natural defense system."

So far, no cancer preventive agents have gained FDA approval, save for a qualified claim for selenium. "This is strikingly odd since many cancer experts agree that the diet plays a strong role in cancer prevention," said Whitacre. But researchers have had a difficult time identifying which nutrients in a healthy diet, other than selenium, actually prevent cancer.

That question was largely answered in 1996 when the late Dr. Larry Clark, of the University of Arizona Cancer Research Center, and Dr. G.F. Combs, Jr., who was Professor at Cornell University at the time (and currently Director of the USDA in Grand Forks, ND), published results from the 10-year Nutritional Prevention of Cancer (NPC) Trial. The NPC Trial which was published in the December, 1996 Journal of the American Medical Association (JAMA), showed Cypress' SelenoExcell(R) brand selenium, taken as a dietary supplement at 200 micrograms per day, powerfully reduced the risk for many types of cancer (colon, lung and prostate) from 50%-63%.

Since then, Cypress Systems, Inc. has campaigned to promote SelenoExcell(R) as cancer preventive food ingredient. SelenoExcell(R) has met all of the requirements cancer researchers demand -- safely proven in randomized, interventional, double blind, placebo-controlled, and long-term human trials. This is the "Gold Standard" of clinical research.

Savvy consumers have been seeking out the SelenoExcell(R) brand of selenium in health stores for over a decade. Today there is the opportunity to fortify foods using the same ingredient that was used in the 10-year study. SelenoExcell, selenium bound to an array of amino acids -- such as cysteine and methionine -- that form proteins, can be incorporated into bread, beverages, and other healthy foods. "Many types of selenium used in dietary supplements are unbound, inorganic, and are not the natural food form of selenium," said Mark Whitacre. "The biological availability of selenium is higher in organically-bound selenium," Whitacre added.

"We at Cypress Systems are placing our full energy behind taking this remarkable cancer prevention research to add this nutrient into normal diets. Our passion and our mission is to use this simple, safe, and inexpensive nutrient to lower cancer risk and prevent a horrible disease that has touched too many Americans' lives," said Whitacre.

More information: http://www.cypsystems.com .

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Cypress Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
2. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
3. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
4. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
5. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
6. IC Sciences Launches ICS Alliance to Advance Development and Adoption of Informatics Instruments for Next Generation Healthcare
7. Biotage Launches New 24 Well Pyrosequencing(R) System
8. Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract
9. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
10. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
11. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
Breaking Biology News(10 mins):